## Incidence, risk factors, and clinical symptom profile of reinfection during Omicron-

# dominated COVID-19 outbreak in Hong Kong: A retrospective cohort study

Ziyang Huang <sup>1, 2, †</sup>, Jingyuan Luo <sup>3, 4, 5, †</sup>, Haoran Li <sup>1</sup>, Xingye Cheng <sup>1</sup>, Jialing Zhang <sup>3, 4, 5</sup>, Hiu To Tang <sup>3, 4</sup>, Hoi Ki Wong <sup>3, 4</sup>, Chun Hoi Cheung <sup>3, 4</sup>, Zhaoxiang Bian <sup>3, 4, 5, \*</sup>, Aiping Lyu <sup>2, 3, 6, \*</sup>, Liang Tian <sup>1, 2, 7, 8, \*</sup>

<sup>1</sup>Department of Physics, Hong Kong Baptist University, Hong Kong, China

<sup>2</sup> Institute of Systems Medicine and Health Sciences, Hong Kong Baptist University, Hong Kong, China

<sup>3</sup> School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China

<sup>4</sup> Vincent V.C Woo Chinese Medicine Clinical Research Institute, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China

<sup>5</sup>Centre for Chinese Herbal Medicine Drug Development, Hong Kong Baptist University, Hong Kong SAR, China

<sup>6</sup>Centre for Cancer & Inflammation Research, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China

<sup>7</sup> Institute of Computational and Theoretical Studies, Hong Kong Baptist University, Hong Kong, China

<sup>8</sup> State Key Laboratory of Environmental and Biological Analysis, Hong Kong Baptist University, Hong Kong, China

<sup>†</sup>These authors contributed equally to this article

\*Corresponding authors:

Liang Tian: SCT904, Cha Chi-ming Science Tower, Ho Sin Hang Campus, Hong Kong Baptist University, 224 Waterloo Road, Kowloon, Hong Kong SAR, China. Email address: <u>liangtian@hkbu.edu.hk</u>;

Aiping Lyu: Jockey Club School of Chinese Medicine Building, 7 Baptist University Road, Kowloon, Hong Kong SAR, China. Email address: <u>aipinglu@hkbu.edu.hk</u>;

Zhaoxiang Bian: Hong Kong Baptist University, 3/F, Jockey Club School of Chinese Medicine Building, 7 Baptist University Road, Kowloon, Hong Kong SAR, China. Email address: <u>bzxiang@hkbu.edu.hk</u>)

## Abstract

Background: Despite the World Health Organization's declaration of the end of the COVID-19 pandemic, reinfection persists and continues to strain the global healthcare system. With the emergence of the most recent variant of SARS-CoV-2 named JN.1, retrospective analysis of epidemiological characteristics of previous cases involving the Omicron variant is essential to provide references for preventing reinfection caused by the ongoing new SARS-Cov-2 variants.

Methods: This retrospective cohort study included 6325 patients infected with SARS - CoV-2 during the Omicron-dominated outbreak (from December 2021 to May 2022) in Hong Kong. Statistical analysis was conducted to demonstrate the epidemiological characteristics and a logistic regression model was utilized to identify risk factors associated with reinfection.

Results: The Omicron reinfection incidence was 5.18% (n = 353). No significant difference was observed in receiving mRNA (BNT162b2) vaccine and inactivated (CoronaVac) vaccine between reinfection and non-reinfection groups (p>0.05). Risk factors were identified as female gender (p<0.001), longer infection duration (p<0.05), comorbidity of eyes, ear, nose, throat disease (p<0.01), and severe postinfection impact on daily life and work (p<0.05), while  $\geq$ 70 years old (p<0.05) and vaccination after primary infection (p<0.01) were associated with a lower risk of reinfection. The prevalence of most symptoms after reinfection was lower than the first infection, except for fatigue.

Conclusion: No significant difference in mRNA (BNT162b2) vaccine and inactivated (CoronaVac) vaccine against reinfection. Post-infection vaccination could lower the risk of reinfection, which

potentially inform the development of preventive measures including vaccination policies against potential new SARS-Cov-2 variants.

Keywords: SARS-CoV-2, COVID-19, Omicron, reinfection, vaccination, risk factors

## 1 1. Introduction

Coronavirus disease 2019 (COVID-19) is a type of infectious disease caused by the coronavirus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1,2]. As reported to WHO, there have been 710 million confirmed cases of COVID-19, including 6.9 million death cases as of September 26, 2023 [3–6]. There were different variants of SARS-CoV-2, including Alpha, Beta, Gamma, Delta, and Omicron, driving multiple infection waves worldwide [7]. The Omicron variant has rapidly become the dominant strain of the virus since its emergence due to immune escapability and high transmissibility [8].

8 The occurrence of reinfection was first confirmed in Hong Kong in August 2022 [9]. Although the World 9 Health Organization (WHO) declared the end of the pandemic in May 2023 [10], the issue of reinfection 10 persists. Previous studies have reported that Omicron reinfection has been occurring globally, with its 11 incidence varying from different regions, such as 12.1% (Omicron BA.2 period) in Shanghai, China [11], 12 28.8% (Omicron BQ.1/BQ.1.1 period) in the U.S. [12], and 0.66% (Omicron BA.1/BA.2 period) in Kyoto, Japan [13]. As of January 5, 2024, the new variant named JN.1, an offspring of Omicron BA.2.86, was 13 14 estimated to comprise approximately 62% of the currently circulating SARS-CoV-2 variants, 15 continuously causing COVID-19 infections to increase globally [14]. It is crucial to retrospectively 16 investigate previous cases of the Omicron variant to provide insights that can aid in developing preventive 17 measures targeting potential new COVID-19 variants.

Apart from reinfection incidence, previous studies have identified several common risk factors associated with reinfection, such as gender, age, and vaccination status, with a particular focus on vaccination against reinfection [11,15–17]. However, other crucial factors that may influence reinfection risk, such as

21 the infection duration of primary infection and post-infection impact on life, have not been thoroughly
22 investigated in the current literature.

23 In Hong Kong, the Omicron variant was the dominant strain of the virus during the fifth wave of the 24 outbreak, leading to over 2.8 million confirmed cases and 13,120 deaths from December 2021 to January 25 2023 [18]. The majority of cases were caused by Omicron BA.2 and its related sublineages (BA.2\*) (85%) [19]. There were two types of COVID-19 vaccines available under the Government Vaccination Program 26 27 in Hong Kong: the BNT162b2 mRNA Vaccine and the CoronaVac/Sinovac inactivated vaccine [20]. The 28 symptom profiles in the acute stage and chronic stage of the Omicron outbreak in Hong Kong have been 29 reported in our previous study [21,22]. Nevertheless, detailed studies on reinfection profiles were still 30 limited. This study was based on a population of COVID-19 patients during the Omicron-dominated 31 outbreak in Hong Kong, to systematically investigate the incidence, risk factors, as well as clinical 32 symptom profile of COVID-19 reinfection.

33

#### 34 **2. Methods**

#### 35 2.1 Study design and population


36 This retrospective cohort study was conducted at the Vincent V.C. Woo Chinese Medicine Clinical Research Institute, Hong Kong Baptist University (HKBU). The data was collected from electronic 37 38 medical records and revisit records via telephone from HKBU. As shown in Figure 1, during the 39 Omicron-dominated outbreak in Hong Kong (December 31, 2021 – May 6, 2022), a total of 6814 patients 40 with confirmed COVID-19 during the Omicron-dominated outbreak in Hong Kong were included. By 41 excluding participants with hospitalization history after infection, 6325 non-hospitalized subjects with 42 primary COVID-19 infection who received consultation services with complete electronic records from 43 the university and revisit information were accounted for in the subsequent analysis. Follow-up telephone 44 visits were conducted to assess the health status, including reinfection status by Chinese medicine

45 physicians (CMPs) and research assistants (RAs) between November 21, 2022, and January 20, 2023. Primary infection and reinfection with SARS-CoV-2 were confirmed via polymerase chain reaction (PCR) 46 or rapid antigen test (RAT). The data was collected under the Compulsory Testing Notice imposed by the 47 48 Hong Kong Government from October 11, 2021 to December 29, 2022, which stated that individuals who 49 have had close contact with confirmed cases of COVID-19 in 2019 but have not exhibited any symptoms 50 of the disease are required to undergo mandatory quarantine at designated quarantine centers [23,24], 51 minimizing the possibility of undetected reinfection among individuals who may be unaware of their 52 reinfection status. The collected data consisted of reinfection status, demographic information, medical 53 history, COVID-19 vaccination information, and post-infection symptoms.

54

### 55 2.2 Outcome

56 The incidence of COVID-19 reinfection was the primary outcome. The definition of reinfection from the 57 CDC was applied in this study: an individual being infected by the SARS-Cov-2 virus, recovering, and 58 then becoming infected again [25]. The investigated factors were as follows: gender, age, Body Mass 59 Index (BMI), vaccination doses (incomplete vaccination: <3 doses; complete vaccination:  $\geq$ 3 doses), vaccine types (BNT162b2, CoronaVac, and others), vaccination after primary infection, infection duration 60 61 (measured in days, from the first positive to the first negative test results by PCR/RAT, comorbidities, 62 treatment for acute stage of illness within four weeks after primary infection & corresponding satisfaction 63 of acute treatment, new disease development after primary infection (new disease types were listed in Table S1), and self-reported post-infection impact on normal life and work in three levels: no impact, 64 65 acceptable impact (mild to moderate), and severe impact. Fifteen clinical symptoms occurring after 66 primary infection and reinfection were recorded.



68 Figure 1. The flowchart of the data selection process.

69

### 70 2.2 Statistical analysis

71 For continuous variables, normally and non-normally distributed variables were expressed as mean 72 (standard deviation, SD) and median (interquartile range, IQR) after testing normality, respectively, while the categorical variables were reported as frequencies and percentages (n%). Student's t-test or Mann-73 74 Whitney U test was used for continuous variables as appropriate, while the Chi-squared test was utilized 75 for categorical variables. To reduce bias arising from the unequal sample sizes between the reinfection 76 group and non-reinfection group, we employed propensity score matching (PSM) [26], a statistical 77 matching technique commonly utilized in observational studies to achieve a balanced distribution of characteristics between control and treatment groups, aiming for a 1:1 ratio of sample size, with 78 79 propensity scores estimated using a logistic regression model (Figure 2). The associations between the 80 risk factors and reinfection were assessed by logistic regression models, expressed as adjusted odd ratios (aOR) and unadjusted odd ratios (OR). Sex, age, BMI, vaccine dose, infection duration during primary 81 82 infection, vaccination after primary infection, comorbidities, new disease development, and post-infection

- 83 life impact were adjusted during the logistic regression analysis. All statistical tests were two-tailed, and
- 84 the significance level was defined as p value < 0.05. Blank values were excluded from the analysis.




Figure 2. Demonstration of propensity score matching using logistic regression. Taking the age factor as an
example, the rest of factors were used for matching.

88

85

#### 89 **3. Results**

90 3.1 Cohort characteristics

The descriptive characteristics of the participant demography were shown in Table 1. The characteristics of the reinfection population were reported as follows: among reinfection patients, the median age was 44 (IQR: 35-58), with 76.77% female and 23.23% male. The median BMI was 22.8 (IQR: 20.7-25.9), and 17.28% were classified as obese. Furthermore, 44.76% of reinfection patients received at least three doses of vaccines, while 21.30% were vaccinated after primary infection. The median infection duration during the first infection was 7 days (IQR: 7-10). 29.75% of them had at least one comorbidity, and 3.68% developed new diseases within the investigated period. Regarding post-infection impact on daily life and

work, 40.23%, 37.96%, and 9.92% of reinfection patients reported no impact, acceptable impact, and
severe impact, respectively. For vaccine types (first vaccine dose), the proportions of mRNA (BNT162b2)
and inactivated (CoronaVac) vaccines were 46.18% and 42.49%, respectively. Time intervals from first
reinfection to primary infection (measured in days) were shown in Figure 3. The median time interval
between primary infection and first reinfection was 279, with a minimum of 97 and a maximum of 333.
The 95% confidence interval ranged from 155.97 to 311.72.

Characteristics Total (N=6325) Reinfection (N = 353)Non-reinfection (N = 5972)**P-value** Gender (n%) 0.009 Female 4276 (67.60%) 271 (76.77%) 239 (67.71%) Male 2049 (32.40%) 82 (23.23%) 114 (32.29%) Age, median [IQR], year 0.001 47 [36, 60] 44 [35, 58] 47 [36, 60] <18 years 473 (7.48%) 20 (5.67%) 453 (7.59%) 0.219 18-29 years 421 (6.66%) 24 (6.80%) 397 (6.65%) 0.999 0.015 30-39 years 1234 (19.51%) 87 (24.65%) 1147 (19.21) 40-49 years 1392 (22.01%) 92 (26.06%) 1300 (21.77) 0.068 50-59 years 1140 (18.02%) 1083 (18.13%) 0.383 57 (16.15%) 60-69 years 1043 (16.49%) 50 (14.16%) 993 (16.63%) 0.255 599 (10.03%) 0.039  $\geq$  70 years 622 (9.83%) 23 (6.52%) BMI, median [IQR], kg/m<sup>2</sup> 22.5 [20.3, 25.1] 22.8 [20.7, 25.9] 22.5 [20.3, 25.1] 0.01 Underweight (<18.5) 336 (5.31%) 13 (3.68%) 323 (5.41%) 0.200 Normal (18.5-23.0) 1691 (26.74%) 90 (25.50%) 1601 (26.81) 0.632 Overweight (23.0<25.0) 668 (10.56%) 35 (9.92%) 633 (10.60%) 0.751 979 (15.48%) 0.375 Obese (≥25.0) 61 (17.28%) 918 (15.37%) 154 (43.63%) Missing 2651 (41.91%) 2497 (41.81%) --0.768 Vaccine doses (n%)  $\geq$ 3 doses 2888 (45.66%) 158 (44.76%) 2730 (45.71%) <3 doses 3437 (54.34%) 195 (55.24%) 3242 (54.29%) Vaccination after infection (n%) 1101 (17.2%) 972 (16.7%) 0.005 129 (21.3%) 7 [6, 9] 7 [7, 10] 7 [6, 9] 0.057 Infection duration, median [IQR],

105 Table 1. The overall demographic characteristics of the patients with follow-up records.

day


•				
At least one comorbidity (n%)	1771 (28.0%)	105 (29.75%)	1666 (27.90%)	0.490
Diabetes	408 (6.45%)	22 (6.23%)	386 (6.46%)	0.952
Hypertension	1050 (16.60%)	60 (17.00%)	990 (16.58%)	0.895
Respiratory disease	127 (2.01%)	7 (1.98%)	120 (2.01%)	1.000
Hyperlipidemia	447 (7.07%)	26 (7.37%)	421 (7.05%)	0.906
Liver disease	49 (0.77%)	4 (1.13%)	45 (0.75%)	0.633
Cardio Cerebrovascular disease	175 (2.77%)	13 (3.68%)	162 (2.71%)	1.000
Renal disease	17 (0.27%)	1 (0.28%)	16 (0.27%)	1.000
Psychological disease	42 (0.66%)	3 (0.85%)	39 (0.65%)	0.916
Neurological disease	11 (0.17%)	0 (0.00%)	11 (0.18%)	0.881
Digestive disease	43 (0.68%)	1 (0.28%)	42 (0.70%)	0.590
Endocrine disease	92 (1.45%)	7 (1.98%)	85 (1.42%)	0.532
Eyes, ear, nose, throat disease	53 (0.84%)	7 (1.98%)	46 (0.77%)	0.033
Other disease	233 (3.68%)	18 (5.10%)	215 (3.60%)	0.219
Treatment within four weeks of diagnosis (n%)	5886 (93.06)	335 (94.90%)	5551 (92.95%)	0.196
Satisfied with the treatment	1149 (18.16%)	90 (25.50%)	1059 (17.73%)	0.343
New disease (n%)	180 (2.85%)	13 (3.68%)	167 (2.80%)	0.420
Post-infection impact (n%)				
No impact	3151 (49.81%)	142 (40.23%)	3009 (50.39%)	0.000
Acceptable impact	2089 (33.02%)	134 (37.96%)	1955 (32.74%)	0.049
Severe impact	437 (6.91%)	35 (9.92%)	402 (6.73%)	0.029
Missing	648 (10.26%)	42 (11.89%)	606 (10.14%)	
Vaccine type - 1 <sup>st</sup> dose (n%)				0.614
mRNA	3110 (49.17%)	163 (46.18%)	2947 (49.35%)	
Inactivated	2690 (42.53)	150 (42.49%)	2540 (42.53%)	
Other & missing	525 (8.30%)	40 (11.33%)	485 (8.12%)	
Vaccine type - 2 <sup>nd</sup> dose (n%)				0.539
mRNA	2970 (46.96%)	153 (43.34%)	2817 (47.17%)	
Inactivated	2480 (39.21%)	138 (39.09%)	2342 (39.22%)	
Other & missing	875 (13.83%)	62 (17.56%)	813 (13.61%)	
Vaccine type - 3 <sup>rd</sup> dose (n%)				0.087
mRNA	1470 (23.24%)	92 (26.06%)	1378 (23.07%)	
Inactivated	1338 (21.15%)	63 (17.85%)	1275 (21.35%)	

Other & missing	3517 (55.6%)	198 (56.09%)	3319 (55.58%)	
Vaccine type - 4 <sup>th</sup> dose (n%)				1.000
mRNA	125 (1.98%)	3 (0.85%)	122 (2.04%)	
Inactivated	65 (1.03%)	2 (0.57%)	63 (1.05%)	
Other & missing	6135 (97.00)	348 (98.58%)	5787 (96.90%)	


106 Data were expressed as median [IQR], n (%), or mean (SD). All tests were two-sided. For vaccine types, only mRNA and

107 inactivated types were included in Chi-square tests.

108



109



112

113 3.2 The incidence of reinfection

The incidence of reinfection was 5.18% (n = 353). Among 353 reinfected patients, 65 (18.41%) of them have experienced reinfection twice (Figure S3). The propensity score matched comparison between the reinfection group and non-reinfection group was shown in Table 2. Compared with non-reinfection

patients, the reinfection group has a higher percentage of females (271, 76.77% vs. 239, 67.71%, p<0.01), younger age population (44, 35-58 vs. 50, 38-62.25, p<0.005), higher BMI (22.8, 20.7-25.9 vs. 22.0, 20.0-24.6, p<0.05). Significant differences were found in post-infection impact on life and work between two groups (p<0.05), among which fewer reinfection patients reported no impact than non-reinfection patients (142, 44.65% vs. 176, 55.35%, p<0.05). Importantly, as shown in Table 3, there were no significant differences found in taking mRNA and inactivated vaccines between the two groups for either dose in four doses (p>0.05).

124

### 125 Table 2. Prevalence of reinfection using propensity score matched patient data.

Characteristics	Reinfection (N = 353)	Non-reinfection (N = 353)	P-value
Gender (n%)			0.009
Female	271 (76.77%)	239 (67.71%)	
Male	82 (23.23%)	114 (32.29%)	
Age, median [IQR], year	44 [35, 58]	50 [38, 62.25]	0.001
BMI, median [IQR], kg/m <sup>2</sup>	22.8 [20.7, 25.9]	22.0 [20.0, 24.6]	0.01
Vaccine dose, median [IQR], dose	2 [2, 3]	2 [2, 3]	>0.05
At least one comorbidity (n%)	105 (29.75%)	91 (25.78%)	>0.05
Infection duration, median [IQR], day	7 [7, 10]	7 [6.75, 10]	>0.05
Post-infection impact (n%)			0.036
No impact	142 (44.65%)	176 (55.35%)	0.013
Acceptable impact	134 (43.09%)	118 (37.11%)	>0.05
Severe impact	35 (11.25%)	24 (7.55%)	>0.05
New disease development	13 (3.69%)	13 (3.69%)	>0.05

126 The propensity score matching was performed among eight factors (bolded). During the matching process of each factor, the

127 other seven factors were matched.

128

#### 129 Table 3. The propensity score matched comparison of vaccine types (mRNA vs. inactivated) of four

130 vaccination status

Vaccine type by status (n%)	Reinfection (N = 353)	Non-reinfection (N = 353)	P-value
1 <sup>st</sup> dose			0.265
mRNA	163 (52.08%)	179 (50.71%)	

Inactivated	150 (47.92%)	136 (38.53%)	
Other & missing	40 (11.33%)	38 (10.76%)	
2 <sup>nd</sup> dose			0.218
mRNA	153 (43.34%)	175 (49.58%)	
Inactivated	138 (39.09%)	2342 (35.98%)	
Other & missing	62 (17.56%)	51 (14.45%)	
3 <sup>rd</sup> dose			0.538
mRNA	92 (26.06%)	80 (22.66%)	
Inactivated	63 (17.85%)	65 (18.41%)	
Other & missing	198 (56.09%)	208 (58.92%)	
4 <sup>th</sup> dose			1.000
mRNA	3 (0.85%)	10 (2.83%)	
Inactivated	2 (0.57%)	4 (1.13%)	
Other & missing	348 (98.58%)	339 (96.03%)	

131 Only mRNA and inactivated types were included in the Chi-square tests. Covariables of sex, age, BMI, comorbidities, infection

132 durations, vaccine doses, new disease development, and post-infection life impact were matched.

133

### 134 3.3 Risk factors associated with the incidence of reinfection

135 Table 4 presented the association between risk factors and reinfection using logistic regression. Several 136 factors were identified to be associated with reinfection. Males exhibited a lower risk of reinfection than 137 females (aOR: 0.619, 0.477-0.804, p<0.001), and individuals that were  $\geq$ 70 years old had a lower 138 reinfection risk than other age groups (aOR: 0.444, 0.231-0.852, p<0.05). A longer infection duration for 139 primary infection was associated with a higher reinfection risk than a shorter infection duration (aOR: 140 1.030, 1.001-1.061, p<0.05). Vaccination after primary infection was significantly associated with a lower 141 risk of reinfection (aOR: 0.708, 0.548-0.916, p<0.01). Having comorbidity of eyes, ear, nose, throat 142 disease could increase the risk of reinfection (aOR: 2.983, 1.316-6.761, p<0.01). In terms of post-143 infection life impact, individuals who experienced either an acceptable impact (aOR: 1.316, 1.027-1.687, 144 p<0.05) or severe impact (aOR: 1.651, 1.108-2.459, p<0.05), compared to those who reported no impact.

145

#### 146 Table 4. Risk factors associated with the prevalence of reinfection.


Factors	Unadjusted Odds Ratio	95% CI	P-value	Adjusted Odds Ratio	95% CI	P-value
Sex, (female as Ref.)	0.616	[0.479, 0.793]	0.000	0.619	[0.477, 0.804]	0.000
Age						
<18 years	0.730	[0.397, 1.342]	0.311	0.877	[0.471, 1.635]	0.680
18-29 years	Ref.			Ref.		
30-39 years	1.255	[0.787, 2.000]	0.340	1.163	[0.726, 1.862]	0.531
40-49 years	1.171	[0.737, 1.860]	0.505	0.993	[0.618, 1.595]	0.977
50-59 years	0.871	[0.533, 1.422]	0.580	0.689	[0.414, 1.147]	0.152
60-69 years	0.833	[0.505, 1.374]	0.474	0.646	[0.378, 1.104]	0.110
≥ 70 years	0.635	[0.354, 1.141]	0.129	0.444	[0.231, 0.852]	0.015
BMI						
Underweight (<18.5)	0.716	[0.395, 1.296]	0.270	0.715	[0.391, 1.307]	0.276
Normal (18.5 < 23.0)	Ref.			Ref.		
Overweight (23.0 < 25.0)	0.984	[0.659, 1.469]	0.936	1.097	[0.730, 1.648]	0.657
Obese (≥25.0)	1.182	[0.846, 1.652]	0.328	1.290	[0.912, 1.825]	0.150
Missing BMI	1.097	[0.840, 1.434]	0.497	1.233	[0.936, 1.624]	0.137
Vaccine dose						
<3 doses	Ref.			Ref.		
>=3 doses	0.788	[0.447, 1.387]	0.409	1.071	[0.853, 1.346]	0.554
Infection duration	1.031	[1.003, 1.060]	0.029	1.030	[1.001, 1.061]	0.046
Missing	1.872	[0.239, 14.674]	0.551	1.803	[0.225, 14.421]	0.579
Vaccination after infection						
NO	Ref.			Ref.		
YES	0.697	[0.545, 0.892]	0.003	0.708	[0.548, 0.916]	0.009
Missing	0.531	[0.313, 0.900]	0.019	0.808	[0.537, 1.217]	0.308
At least one comorbidity, n (%)						
Diabetes	0.919	[0.560, 1.508]	0.738	1.067	[0.637, 1.787]	0.805
Hypertension	1.022	[0.742, 1.408]	0.894	1.322	[0.924, 1.890]	0.126
Respiratory disease	0.955	[0.441, 2.067]	0.908	0.873	[0.400, 1.907]	0.734
Hyperlipidemia	1.048	[0.657, 1.671]	0.845	1.145	[0.701, 1.868]	0.589
Liver disease	1.544	[0.551, 4.327]	0.409	1.767	[0.624, 5.003]	0.284
Cardio-cerebrovascular disease	1.321	[0.766, 2.280]	0.317	1.636	[0.929, 2.881]	0.088
Renal disease	0.993	[0.130, 7.600]	0.995	1.396	[0.179, 10.916]	0.750

Psychological disease	1.177	[0.359, 3.865]	0.788	1.137	[0.342, 3.778]	0.834
Endocrine disease	1.392	[0.637, 3.038]	0.407	1.236	[0.560, 2.729]	0.600
Eyes, ear, nose, throat disease	2.643	[1.182, 5.910]	0.018	2.983	[1.316, 6.761]	0.009
New disease development	1.329	[0.748, 2.361]	0.333	1.073	[0.594, 1.938]	0.816
Post-infection impact						
No impact	Ref.			Ref.		
Acceptable impact	1.452	[1.139, 1.852]	0.003	1.316	[1.027, 1.687]	0.030
Severe impact	1.845	[1.256, 2.709]	0.002	1.651	[1.108, 2.459]	0.014
Missing	1.469	[0.040, 0.056]	0.034	1.522	[1.057, 2.191]	0.024


147

### 148 3.4 Symptom profiles of reinfection

149 Figure 4 shows the symptom profile of the first reinfection and primary infection of the same population 150 (n = 278), which included the prevalence of 15 symptoms among those who were reinfected once. The 151 top 5 most prevalent symptoms after reinfection were identified as follows: fatigue (34.17%), cough 152 (33.09%), sputum (12.95%), headache (10.79%), and muscle pain (9.71%). Significant differences were 153 observed in most of the symptoms between the reinfection group and the primary infection group. Among 154 them, cough, sputum, dry throat, sore throat, itchy throat, abdominal distension, and diarrhea showed 155 highly significant differences (p < 0.001), while chest tightness, abdominal pain, and nausea exhibited 156 significant differences (p<0.01). For those who had a primary infection and reinfection afterward, their 157 symptom types experienced during reinfection were generally similar to those observed during the 158 primary infection. The prevalence of most of the investigated symptoms after reinfection was lower than 159 that observed during the primary infection.



160



164

## 165 **4. Discussion**

To our knowledge, this study investigated the incidence, risk factors, and clinical symptom profile of 166 Omicron reinfection in Hong Kong for the first time, with a large sample size and an overall age 167 168 distribution. Based on our results, the reinfection incidence was 5.18% during the Omicron outbreak in Hong Kong, which was different from other studies. A reinfection rate of 11.5% was reported in Iceland 169 170 during the Omicron period [27]. A study conducted in Korea reported a reinfection rate of 3% during the 171 Omicron BA.2 period [28]. The reinfection incidence was 0.66% (Omicron BA.1-dominated period) in Kyoto, Japan [13]. In general, the reinfection rates from different areas reflect that the Omicron variant 172 173 has been a persistent threat to the global healthcare system.

174 Our finding suggested that females were more likely to have reinfection, which aligned with the cases 175 observed in primary infection in previous studies [22,29,30]. With respect to age, a plausible explanation 176 for the increased susceptibility to reinfection among individuals over 70 years old could be their tendency 177 to have fewer social interactions or lower exposure to high-risk environments compared to younger 178 individuals, which may reduce their chances of encountering situations that lead to reinfection [13]. 179 According to a report from the CDC, patients with a weakened immune system are more likely to be 180 infected with COVID-19 for a more extended period [31]. Therefore, a longer duration of primary 181 infection could increase the risk of reinfection, which may imply that individuals with a lower level of 182 immune response could be more susceptible to reinfection. Additionally, comorbidity of ear, nose, throat 183 disease may compromise immune barrier function in the nasal and pharyngeal regions, potentially 184 increasing susceptibility to reinfections. Individuals who experienced a severe impact on life and work 185 were at a higher risk of reinfection, which may also be attributed to residual immune deficiencies 186 following primary infection recovery [31]. These hypotheses require further research to be confirmed.

187 Notably, vaccination after primary infection was associated with a lower risk of reinfection, which was in 188 line with several other studies [32,33]. Our results also suggested no significant difference found in reinfection rates between the CoronaVac vaccine and the BNT162b2 vaccine. However, a previous study 189 190 has reported that receiving mRNA vaccines leads to a lower reinfection rate than inactivated vaccines [34]. 191 while another study suggested that Combined vaccination may offer superior reinfection protection than 192 either alone [35]. Considering the potential long-term persistence of the SARS-CoV-2 virus, individuals 193 with relatively lower immune responses may benefit from a booster vaccination after primary infection, 194 and further investigations were required to confirm the effects of different vaccine types.

Regarding the clinical symptom profile, the incidence of most reinfection symptoms was significantly lower than primary infection. This was consistent with a study reporting that 80.7% of the reinfection patients had mitigated or similar clinical symptoms compared with their first infection [11]. However, the prevalence of fatigue did not exhibit a significant difference. Fatigue, as one of the most common

199	symptoms of long COVID, is prone to persist with repeated infections [21,36]. The lack of medications
200	specifically targeting post-infection fatigue in COVID-19 patients requires further research.

201

202 4.1 Strengths and limitations

The strengths of our study are as follows. PSM was utilized in statistical analysis to balance the unequal sample sizes of the reinfection and non-reinfection groups, thereby making our results more reliable. In addition to demographic factors, several additional factors such as infection duration during primary infection, comorbidity of eyes, ear, nose, throat disease, and impact on life and work after primary infection were accounted for the first time in this study. Clinical symptoms of reinfection versus the first infection were analyzed in this study, providing a more comprehensive understanding of the reinfection profile.

There are several limitations in our study. First, the reinfection incidence might be underestimated as some reinfected individuals might not have been diagnosed. Second, follow-up records via telephone may introduce subjective bias and affect data reliability. Furthermore, the investigated population was regional and limited to Hong Kong, which may not represent the general population well.

214

#### 215 **5. Conclusion**

In conclusion, this retrospective cohort study investigated the prevalence, risk factors, and symptom profile of COVID-19 reinfection during the Omicron-dominated outbreak in Hong Kong. No significant difference was found in the BNT162b2 vaccine and the CoronaVac vaccine. Populations with female gender, longer infection duration, having comorbidity of eyes, ear, nose, throat disease, having postinfection life impact, and no vaccination after primary infection were identified to be more susceptible to experience reinfection, while being  $\geq$ 70 years old exhibited a lower reinfection risk. Fewer patients

242	Ethics approval and consent to participate
241	Declarations
240	
239	OR: unadjusted odd ratios
238	aOR: adjusted odd ratios
237	PSM: propensity score matching
236	IQR: interquartile range
235	SD: standard deviation
234	RAT: rapid antigen test
233	PCR: polymerase chain reaction
232	WHO: World Health Organization
231	SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2
230	COVID-19: Coronavirus disease 2019
229	Abbreviations
228	
227	reinfection outbreaks and the associated health ramifications arising from reinfection occurrences.
226	nature of the virus. This study has the potential to provide valuable insights pertaining to the prevention of
225	after infection, and ongoing updates for vaccines are also imperative to effectively combat the evolving
224	the development of epidemic preventive measures, particularly policies regarding booster vaccination
223	compared to their first infection. Notably, the finding of vaccination after infection can potentially inform
222	reported experiencing the majority of investigated clinical symptoms except fatigue during reinfection

243	Ethics committee of Hong Kong Baptist University waived ethical approval for this work. Informed
244	consent for the telephone-visit data collection was provided by all patients. The reporting of this study is
245	in accordance with the recommendations of the STROBE (Strengthening the Reporting of Observational
246	Studies in Epidemiology) guidelines [37].
247	
248	Consent for publication
249	All authors meet the requirements for authorship as stated in this document and have read and approved
250	the final manuscript.
251	
252	Availability of data and materials
253	Individual, de - identified patient data can be available upon request from the corresponding authors.
254	
255	Competing interests
256	The authors declare that they have no known competing financial interests or personal relationships that
257	could have appeared to influence the work reported in this paper.
258	
259	Funding
260	This research is supported by the Research Grants Council of Hong Kong (Grant No. C2005-22Y), the
261	National Natural Science Foundation of China (Grant No. 12275229), and the Hong Kong Chinese
262	Medicine Development Fund (Grant No. 22B2/049A).
263	

264	Author cont	ribution
265	L Tian, A L	yu, and Z Bian conceived and designed the study; Z Huang performed all the statistical
266	analysis. Z l	Huang, J Luo, L Tian, A Lyu, and Z Bian interpreted the results. H Li and X Cheng
267	contributed to	o the data processing; J Luo, J Zhang, H Wong, H To Tang, and C Cheung collected the raw
268	data. Z Huar	ng and J Luo wrote the manuscript; L Tian, A Lyu and Z Bian edited the manuscript. All
269	authors read	and approved the manuscript.
270		
271	Acknowledg	ements
272	We thank Lei	han Tang, Linda Zhong, and Xin Xiong for valuable discussions.
273		
274	Reference	
275	[1]	WHO. Coronavirus disease (COVID-19). 2021 n.d. https://www.who.int/health-
276		topics/coronavirus#tab=tab_1 (accessed November 12, 2023).
277	[2]	WHO. Coronavirus disease (COVID-19) pandemic. 2022 n.d.
278		https://www.who.int/europe/emergencies/situations/covid-19 (accessed November 8,
279		2023).
280	[3]	WHO. WHO Director-General's opening remarks at the media briefing on COVID-19 - 11
281		March 2020 2020. https://www.who.int/director-general/speeches/detail/who-director-
282		general-s-opening-remarks-at-the-media-briefing-on-covid-1911-march-2020 (accessed
283		December 12, 2023).
284	[4]	Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. The proximal origin of SARS-
285		CoV-2. Nat Med 2020;26:450–2. https://doi.org/10.1038/s41591-020-0820-9.

- 286 [5] Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus associated with
- 287 human respiratory disease in China. Nature 2020;579:265–9.
- 288 https://doi.org/10.1038/s41586-020-2008-3.
- 289 [6] Zhou P, Yang X Lou, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak
- associated with a new coronavirus of probable bat origin. Nature 2020;579:270–3.
- 291 https://doi.org/10.1038/s41586-020-2012-7.
- 292 [7] WHO. WHO Coronavirus (COVID-19) Dashboard n.d. https://covid19.who.int/ (accessed
  293 November 12, 2023).
- WHO. Tracking SARS-CoV-2 variants n.d. https://www.who.int/activities/tracking-SARS CoV-2-variants (accessed November 8, 2023).
- 296 [9] Kai-Wang To K, Fan-Ngai Hung I, Daniel Ip J, Wing-Ho Chu A, Chan W-M, Raymond Tam A,
  297 et al. COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain
- 298 confirmed by whole genome sequencing. n.d.
- 299 [10] World Health Organization. WHO Director-General's opening remarks at the media
- 300 briefing 5 May 2023 n.d. https://www.who.int/director-general/speeches/detail/who-
- 301 director-general-s-opening-remarks-at-the-media-briefing---5-may-2023 (accessed
   302 February 21, 2024).
- 303[11]Lin M, Cao K, Xu F, Wu X, Shen Y, Lu S, et al. A follow-up study on the recovery and304reinfection of Omicron COVID-19 patients in Shanghai, China. Emerg Microbes Infect3052023;12. https://doi.org/10.1080/22221751.2023.2261559.
- 306 [12] Ma KC, Dorabawila V, León TM, Henry H, Johnson AG, Rosenberg E, et al. Trends in
   307 Laboratory-Confirmed SARS-CoV-2 Reinfections and Associated Hospitalizations and

308	Deaths Among Adults Aged ≥18 Years — 18 U.S. Jurisdictions, September 2021–December
309	2022. 2021.

- 310 [13] Nagao M, Matsumura Y, Yamamoto M, Shinohara K, Noguchi T, Yukawa S, et al. Incidence
- 311 of and risk factors for suspected COVID-19 reinfection in Kyoto City: a population-based
- 312 epidemiological study. European Journal of Clinical Microbiology and Infectious Diseases
- 313 2023;42:973–9. https://doi.org/10.1007/s10096-023-04625-6.
- 314 [14] COVID-19 Activity Increases as Prevalence of JN.1 Variant Continues to Rise 2024.
- 315 https://www.cdc.gov/respiratory-viruses/whats-new/JN.1-update-2024-01-05.html
  316 (accessed January 19, 2024).
- Ukwishaka J, Ndayishimiye Y, Destine E, Danwang C, Kirakoya-Samadoulougou F. Global
   prevalence of coronavirus disease 2019 reinfection: a systematic review and meta-analysis.
   BMC Public Health 2023;23. https://doi.org/10.1186/s12889-023-15626-7.
- Ice JH, Hwang JH, Jang EJ, Kim RK, Lee KH, Park SK, et al. Risk Factors Related to COVID-19
   Reinfection and Fatality During the Omicron (BA.1/BA.2) Period in Korea. J Korean Med Sci
   2023;38. https://doi.org/10.3346/jkms.2023.38.e269.
- Flacco ME, Acuti Martellucci C, Baccolini V, De Vito C, Renzi E, Villari P, et al. COVID-19
  vaccines reduce the risk of SARS-CoV-2 reinfection and hospitalization: Meta-analysis.
  Front Med (Lausanne) 2022;9. https://doi.org/10.3389/fmed.2022.1023507.
- 326 [18] The Government of the Hong Kong Special Administrative Region. Archive of statistics on
- 327 5th wave of COVID-19. n.d.

- 328 [19] Xie R, Edwards KM, Adam DC, Leung KSM, Tsang TK, Gurung S, et al. Resurgence of
- 329 Omicron BA.2 in SARS-CoV-2 infection-naive Hong Kong. Nat Commun 2023;14.
- 330 https://doi.org/10.1038/s41467-023-38201-5.
- The Government of the Hong Kong Special Administrative Region. COVID-19 Vaccination
   Programme FAQs 2024. https://www.chp.gov.hk/en/features/106953.html (accessed
   January 19, 2024).
- I 21] Luo J, Zhang J, Tang HT, Wong HK, Lyu A, Cheung CH, et al. Prevalence and risk factors of
- long COVID 6–12 months after infection with the Omicron variant among nonhospitalized
- patients in Hong Kong. J Med Virol 2023;95. https://doi.org/10.1002/jmv.28862.
- 337 [22] Luo J, Zhang J, Tang HT, Wong HK, Ma Y, Xie D, et al. Weekly symptom profiles of
- 338 nonhospitalized individuals infected with SARS-CoV-2 during the Omicron outbreak in
- 339 Hong Kong: A retrospective observational study from a telemedicine center. J Med Virol
- 340 2023;95. https://doi.org/10.1002/jmv.28447.
- 341 [23] The Government of the Hong Kong Special Administrative Region. Government gazettes
   342 compulsory testing notice n.d.
- 343 https://www.info.gov.hk/gia/general/202110/11/P2021101101006.htm?fontSize=1
   344 (accessed February 19, 2024).
- 345 [24] The Government of the Hong Kong Special Administrative Region. Government adjusts
  346 local anti-epidemic measures n.d.
- 347 https://www.info.gov.hk/gia/general/202212/29/P2022122900035.htm?fontSize=1
- 348 (accessed February 19, 2024).

- 349 [25] CDC. What is COVID-19 Reinfection? 2023. https://www.cdc.gov/coronavirus/2019-
- 350 ncov/your-health/reinfection.html (accessed February 1, 2024).
- 351 [26] Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies 352 for causal effects. vol. 70. 1083.
- 353 [27] Eythorsson E, Runolfsdottir HL, Ingvarsson RF, Sigurdsson MI, Palsson R. Rate of SARS-CoV-
- 2 Reinfection during an Omicron Wave in Iceland. JAMA Netw Open 2022;5:E2225320.
- 355 https://doi.org/10.1001/jamanetworkopen.2022.25320.
- 356 [28] Lee JH, Hwang JH, Jang EJ, Kim RK, Lee KH, Park SK, et al. Risk Factors Related to COVID-19
- Reinfection and Fatality During the Omicron (BA.1/BA.2) Period in Korea. J Korean Med Sci
  2023;38:e269. https://doi.org/10.3346/jkms.2023.38.e269.
- 359 [29] Abdelrahman MM, Abd-Elrahman NM, Bakheet TM. Persistence of symptoms after
- 360 improvement of acute COVID19 infection, a longitudinal study. J Med Virol 2021;93:5942–
- 361 6. https://doi.org/10.1002/jmv.27156.
- 362 [30] Adrielle dos Santos L, Filho PG de G, Silva AMF, Santos JVG, Santos DS, Aquino MM, et al.
- 363 Recurrent COVID-19 including evidence of reinfection and enhanced severity in thirty
- 364 Brazilian healthcare workers. Journal of Infection 2021;82:399–406.
- 365 https://doi.org/10.1016/j.jinf.2021.01.020.
- 366 [31] CDC. People Who Are Immunocompromised 2023.
- 367 https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-who-are-
- 368 immunocompromised.html (accessed January 19, 2024).

369	[32]	Lewis N, Chambers LC, Chu HT, Fortnam T, De Vito R, Gargano LM, et al. Effectiveness
305	[JZ]	Eewis N, Chambers EC, Chu Th, Fortham T, De vito N, Gargano Ewi, et al. Enectivenes

- 370 Associated with Vaccination after COVID-19 Recovery in Preventing Reinfection. JAMA
- 371 Netw Open 2022;5:E2223917. https://doi.org/10.1001/jamanetworkopen.2022.23917.
- 372 [33] Cavanaugh AM, Spicer KB, Thoroughman D, Glick C, Winter K. Reduced Risk of Reinfection
  373 with SARS-CoV-2 After COVID-19 Vaccination Kentucky, May-June 2021. 2021.
- 374 [34] Tan-Lim CSC, Gonzales MLAM, Dans LF, Cordero CP, Alejandria MM, dela Paz ECC, et al.
- 375 Reinfection rates, change in antibody titers and adverse events after COVID-19 vaccination
- 376 among patients previously infected with COVID-19 in Metro Manila, Philippines: a
- 377 secondary analysis of a completed cohort study. BMC Infect Dis 2023;23.
- 378 https://doi.org/10.1186/s12879-023-08743-6.
- 379 [35] Vicentini M, Venturelli F, Mancuso P, Bisaccia E, Zerbini A, Massari M, et al. Risk of SARS-
- 380 CoV-2 reinfection by vaccination status, predominant variant and time from prior infection:
- 381 a cohort study, Reggio Emilia province, Italy, February 2020 to February 2022.
- 382 Eurosurveillance 2023;28. https://doi.org/10.2807/1560-7917.ES.2023.28.13.2200494.
- 383 [36] O'Mahoney LL, Routen A, Gillies C, Ekezie W, Welford A, Zhang A, et al. The prevalence and
- 384 long-term health effects of Long Covid among hospitalised and non-hospitalised
- 385 populations: A systematic review and meta-analysis. EClinicalMedicine 2023;55.
- 386 https://doi.org/10.1016/j.eclinm.2022.101762.
- 387 [37] von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The
- 388 Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement:
- 389 guidelines for reporting observational studies. J Clin Epidemiol 2008;61:344–9.
- 390 https://doi.org/10.1016/j.jclinepi.2007.11.008.

- 391
- 392
- 393